BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track

BIOMARIN PHARMACEUTICAL INC

2025-FY EPS reported $1.80 revenue$3,221,253,000

Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).
Q4 GAAP net loss of $47M vs $125M income prior year; Non-GAAP income $89M vs $180M.
ROCTAVIAN withdrawal triggered ~$240M Q4 charges ($119M inventory write-off, $118M asset impairments).
VOXZOGO FY revenue $927M (+26% Y/Y); PALYNZIQ $433M (+22% Y/Y).
2026 guidance provided (ex-Amicus); Amicus acquisition expected to close in Q2'26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.